Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jelle Klein

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinical Neurology and Neurosurgery|January 24, 2016
Predicting discharge destination after stroke: A systematic reviewMargot Mees, Jelle Klein, Laetitia Yperzeele, et al.
British Journal of Clinical Pharmacology|March 8, 2026
Why do healthy volunteers participate in clinical trials?Thijs van Iersel, Jelle Klein, Timothy C Hardman, et al.
Virology Journal|May 15, 2024
Proof of stability of an RSV Controlled Human Infection Model challenge agentSandra Verstraelen, Dirk Roymans, An Jacobs, et al.
Pulmonary Pharmacology & Therapeutics|April 25, 2024
Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellantFrançois Rony, Mauro Cortellini, Alessandro Guasconi, et al.
The Lancet. Microbe|May 10, 2024
Assessment of CD8<sup>+</sup> T-cell mediated immunity in an influenza A(H3N2) human challenge model in Belgium: a single centre, randomised, double-blind phase 2 studyThomas G Evans, Flora Castellino, Monika Kowalik Dobczyk, et al.
Ebiomedicine|January 19, 2022
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I studyOdile Launay, Cécile Artaud, Marie Lachâtre, et al.
Nature Medicine|July 1, 2026
Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infectionLoukas Papargyris, Jiayun Xu, Claire Broderick, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical Neurology and Neurosurgery|January 24, 2016
Predicting discharge destination after stroke: A systematic reviewMargot Mees, Jelle Klein, Laetitia Yperzeele, et al.
British Journal of Clinical Pharmacology|March 8, 2026
Why do healthy volunteers participate in clinical trials?Thijs van Iersel, Jelle Klein, Timothy C Hardman, et al.
Virology Journal|May 15, 2024
Proof of stability of an RSV Controlled Human Infection Model challenge agentSandra Verstraelen, Dirk Roymans, An Jacobs, et al.
Pulmonary Pharmacology & Therapeutics|April 25, 2024
Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellantFrançois Rony, Mauro Cortellini, Alessandro Guasconi, et al.
The Lancet. Microbe|May 10, 2024
Assessment of CD8<sup>+</sup> T-cell mediated immunity in an influenza A(H3N2) human challenge model in Belgium: a single centre, randomised, double-blind phase 2 studyThomas G Evans, Flora Castellino, Monika Kowalik Dobczyk, et al.
Ebiomedicine|January 19, 2022
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I studyOdile Launay, Cécile Artaud, Marie Lachâtre, et al.
Nature Medicine|July 1, 2026
Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infectionLoukas Papargyris, Jiayun Xu, Claire Broderick, et al.
Pageof 1